Pharma Exclusives Pressreleases
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Wednesday, December 04, 2024Teva Pharmaceutical Industries Ltd presented positive data from its Phase SPACE study evaluating the efficacy and safety of AJOVY fremanezumab for the prevention of episodic migraine in children and adolescent patients aged years The trial showed s...
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Tuesday, December 03, 2024Hansa Biopharma Hansa and Genethon a pioneer and a leader in gene therapy research and development for rare genetic diseases today announced initiation of GNTIDES a Phase trial in patients with CriglerNajjar syndrome with preexisting antibodies agai...
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Tuesday, December 03, 2024Ipsen and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX BMX is a bispecific antibody that engages and activates a subset of cytotoxic T cells called MucosalAssociated Invariant T cells MAIT cells and targets...
